MedTrace Logo

Effects of Arterin Cholesterol for Reduction of Lipid Levels

NCT04749784 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-02-11

No results posted yet for this study

Summary

The main objective of this double-blind, randomised, placebo-controlled study is to assess the benefit and tolerability of Arterin Cholesterol in subjects with elevated lipid levels within a 12-week period of use.

Conditions

  • Blood Cholesterol Lowers
  • LDL-C

Interventions

DIETARY_SUPPLEMENT

High Dose Arterin Cholesterol

240mg active ingredient daily

DIETARY_SUPPLEMENT

Low Dose Arterin Cholesterol

120mg active ingredient daily

DIETARY_SUPPLEMENT

Placebo

Placebo tablet

Sponsors & Collaborators

  • Analyze & Realize

    collaborator NETWORK

  • Perrigo CSCI

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack, MD · Analyze & Realize

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749784 on ClinicalTrials.gov